Immunological features in de novo and recurrent glioblastoma associate with survival outcomes.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-1050
Abstract: Glioblastoma (GBM) is an immunologically "cold" tumor characterized by poor responsiveness to immunotherapy. Standard-of-care for GBM is surgical resection followed by chemoradiotherapy and maintenance chemotherapy. However, tumor recurrence is the norm, and recurring tumors are… read more here.
Keywords: features novo; glioblastoma; novo recurrent; glioblastoma associate ... See more keywords